Searchable abstracts of presentations at key conferences in endocrinology

ea0029p1519 | Pituitary Clinical | ICEECE2012

Pituitary macroadenomas: benefit from early GH substitution after surgery

Sauer N. , Dannheim V. , Flitsch J. , Aberle J.

Introduction: of non-functioning pituitary macroadenomas are associated with hyposecretion of the pituitary gland. In addition surgical therapy can lead to a partial or complete hypopituitarism. Data suggest that substitution of growth hormone can improve quality of life and reduce associated symptoms. However in many cases substitution is not started within the first 6–12 months after surgery. Therefore we intended to investigate if patients benefit from an early growth ...

ea0029p1505 | Pituitary Clinical | ICEECE2012

DHEAS: a new marker in Cushing’s disease? Preliminary results of 32 patients

Burkhardt T , Aberle J , Mengel M , Jorg F

Introduction/objective: The objective was to determine if peri-operative levels of DHEAS correlate with levels of ACTH and cortisol and therefore are useful as a new marker for the definition of cure in patients suffering from Cushing’s disease. DHEAS is an ACTH-dependent precursor of androgens and estrogens secreted from the adrenals. Numerous clinical trials have shown that DHEAS in humans and other mammals is a multi-functional steroid implicated in a broad range of bi...

ea0056p321 | Clinical case reports - Thyroid/Others | ECE2018

Effect of hemoglobin J variant on HbA1c values as measured by HPLC (high-perfomance liquid chromatography)

Ares Blanco Jessica , Bernardo Gutierrez Angel , Martin-Nieto Alicia , Gonzalez-Martinez Silvia , Delgado-Alvarez Elias , Menendez-Torre Edelmiro

Hemoglobin A1c (HbA1c) is used for the long-term management of patients with diabetes mellitus (DM). Hemoglobin variants other than HbA1c and e-N-lysine-glycated HbA0 may cause analytical interference in determinations of HbA1c. Hemoglobin J is an abnormal hemoglobin, an alpha globin gene variant and present in various geographic locations. Hemoglobin J (depending on its type) has different characteristics and functions. For example hemoglobin J Capetown (α2 92Gln β2...

ea0090p761 | Thyroid | ECE2023

J – 131 therapy of autonomously functioning thyroid adenoma: the outcome of our 20 – years experience

Petrovski Zlatko

Objective: To investigate the results of J – 131 treatments in patients (pts) with autonomous thyroid adenomas in long period of follow up.Material and Methods: We enrolled 68 consecutive pts with Plummer’s disease (50 females, 18 males, mean age 54,7 yrs, range 21 – 79 yrs) for period 2000 – 2020 yrs. 87%(59/68) pts had a unifocal nodule, while 13% (9/68) pts had multifocal toxic autonomous nodules. Pts stopped antithyroid drugs for ...

ea0029p1242 | Obesity | ICEECE2012

Obesity related comorbidities 2 years following bariatric surgery in a group of 215 German subjects

Sauer N. , Wienecke J. , Schulze zur Wiesch C. , Reining F. , Wolter S. , Dupree A. , Mann O. , Aberle J.

Background: Bariatric surgery has shown to effectively reduce body weight and the prevalence of obesity associated comorbidities. However, especially data concerning diabetes is still conflicting. Also the benefit of surgical therapy varies strongly depending on individual patient characteristics.Methods: Therefore we intended to investigate a heterogeneous group of obese patients (n=215) undergoing bariatric surgery in terms of related comorbidit...

ea0025pl3biog | Society for Endocrinology Transatlantic Medal Lecture | SFEBES2011

Society for Endocrinology Transatlantic Medal Lecture

Kopchick J J

J J Kopchick, Ohio University, Athens, Ohio, USA. AbstractDr John J Kopchick is an internationally recognized leader in the growth hormone (GH) field. Since 1987, he has held the Milton and Lawrence H Goll Eminent Scholar Professorship in Molecular and Cellular Biology and directs the Growth/Obesity/Diabetes Section of the Edison Biotechnology Institute at Ohio University in Athens, Ohio. He also is Professor in the B...

ea0035p581 | Endocrine tumours and neoplasia | ECE2014

Is early repeat surgery a feasible concept for potential incomplete resection in acromegaly?

Rotermund Roman , Lautenbach Anne , Burkhardt Till , zur Wisch Clarissa Schulze , Aberle Jens , Flitsch Jorg

Transsphenoidal surgery is the treatment of choice for acromegaly. Cure is defined by normalization of age-related IGF1 and sufficient suppression of GH in the oral glucose tolerance test (OGTT). We investigated, if early postoperative hormone testing gives reliable information whether complete resection of a tumor was achieved and compared these findings with further follow-up data.So far, 22 patients underwent OGTT within a week after surgery, starting...

ea0032p760 | Obesity | ECE2013

Off-label GLP-1 agonist treatment in 43 non-diabetic patients: are weight loss and treatment tolerance equally promising outside of clinical trials?

Sauer Nina , Rohani Zaina , Wiesch Clarissa Schulze zur , Reining Franziska , Aberle Jens

Context: Recent data from controlled clinical trials have demonstrated that GLP-1 agonists are a well-tolerated therapy-option for weight loss in obese patients without type 2 diabetes mellitus.Objective: To investigate whether continuation of treatment, side-effects and effect on weight loss of GLP-1 agonists are equally promising in dairy clinical practice settings in non-diabetics.Methods: Obese, non-diabetic patients of our int...

ea0035s22.3 | Novel therapies for thyroid cancer | ECE2014

Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer

Fagin J

Oncogenic activation of MAPK in thyroid cells leads to loss of expression of genes required for thyroid hormone biosynthesis, including the sodium iodide transporter (NIS) and thyroid peroxidase (TPO). Tumors with BRAF mutation have lower expression of NIS, explaining in part why BRAF-mutant PTCs are often resistant to RAI therapy. We developed mouse models of thyroid cancer driven by BRAFV600E, and these tumors also lose the ability to concentrate radioiodine, whic...

ea0019s1biog | Society for Endocrinology Jubilee Medal Lecture | SFEBES2009

Society for Endocrinology Jubilee Medal Lecture

Wass J

J Wass, Department of Endocrinology, OCDEM, Churchill Hospital, Oxford, UK AbstractJohn Wass is the Professor of Endocrinology at Oxford University and Head of the Department of Endocrinology at the Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital Oxford, UK. He qualified at Guy’s in 1971 and did his endocrine training at Bart’s. He got his MD from the University of London in 1980....